TrialJournal of Korean medical science2018

Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.

Soon Ki Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.